Atipamezole Hydrochloride

Verify with FDA CVM →

1,561 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
1,561
Total Reports
266
Deaths Reported
1700.0%
Death Rate

Active Ingredients

Atipamezole Hydrochloride

Administration Routes

IntramuscularUnknownIntravenousSubcutaneousParenteralOtherIntraperitonealOphthalmicOral

Species Affected

Dog 980
Cat 439
Unknown 111
Rabbit 4
Human 4
Other Rodents 3
Tiger 2
Mouse 2
Chinchilla 2
Rat 2

Most Affected Breeds

Domestic Shorthair 242
Unknown 133
Retriever - Labrador 119
Dog (unknown) 85
Terrier - Bull - American Pit 60
Domestic Longhair 52
Shepherd Dog - German 45
Cat (other) 37
Cat (unknown) 31
Retriever - Golden 30

Most Reported Reactions

Death 189
INEFFECTIVE, REVERSAL 182
Bradycardia 168
Lack of efficacy - NOS 154
Vomiting 139
Lethargy (see also Central nervous system depression in 'Neurological') 124
Sedation prolonged 121
Hypersalivation 116
Cardiac arrest 103
Panting 96
Diarrhoea 94
Seizure NOS 87

Outcome Breakdown

Ongoing
577 (39.4%)
Recovered/Normal
478 (32.6%)
Died
206 (14.1%)
Outcome Unknown
140 (9.6%)
Euthanized
62 (4.2%)
Recovered with Sequela
2 (0.1%)

Data Summary

Metric Value
Total adverse event reports 1,561
Reports involving death 266
Case-fatality rate (reported events) 1700.0%
Distinct species in reports 10
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Atipamezole Hydrochloride Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 1,561 adverse event reports referencing Atipamezole Hydrochloride, including 266 reports in which the animal died — a 1700.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Atipamezole Hydrochloride. Reported administration routes include Intramuscular, Unknown, Intravenous, Subcutaneous. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Atipamezole Hydrochloride reports are Dog (980 reports), Cat (439 reports), Unknown (111 reports), with Dog accounting for the largest share. Within those species, Domestic Shorthair (242), Unknown (133), Retriever - Labrador (119) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Atipamezole Hydrochloride are Death (189), INEFFECTIVE, REVERSAL (182), Bradycardia (168), Lack of efficacy - NOS (154). Of the 1,465 reports with a coded outcome, Ongoing is the leading category at 39.4%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Atipamezole Hydrochloride.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial